NHS Trials Ultra-Fast Brain Scans to Expedite Dementia Diagnosis

The National Health Service (NHS) is piloting ultra-fast brain scans and other new technologies in an effort to significantly reduce the time it takes to diagnose dementia. Researchers hope to cut patient time in an MRI scanner from the current 20 minutes to as little as six, while still gathering essential diagnostic information.

This technological advancement is crucial as MRI scans are increasingly required for accurate dementia diagnosis, determining eligibility for new Alzheimer's drugs, and monitoring their effectiveness. However, a severe shortage of scanners in the UK has created a significant bottleneck, leading to prolonged delays for patients. Reducing scan times by approximately 70% could dramatically improve access, lower costs, and make the imaging process more comfortable for patients.

The faster scans are part of a broader £80 million taxpayer-funded research project involving nine new technologies. The overarching goal is to drastically accelerate the diagnostic timeline, with a target of diagnosing 92% of individuals within 18 weeks of referral to a memory clinic, a significant increase from the current rate of 60%, where diagnoses can often take over a year.

Early diagnosis offers several benefits, including a reduced likelihood of emergency hospital admissions, delayed need for extensive care support, and a lessened impact on the NHS. It also enables patients to commence treatment sooner and make informed decisions regarding their work, finances, family life, and personal care.

The ultra-fast scan trial, led by University College London, is collaborating with major MRI scanner manufacturers—Philips, Siemens, and GE—across 20 NHS sites to integrate these technologies into dementia care. The research is supported by the Department for Business, Innovation, Science and Trade (BIST) through UK Research and Innovation (UKRI).

Additional technologies being tested include remote monitoring of cognitive decline via digital devices, home monitoring equipment and body sensors to detect subtle behavioral changes, and blood biomarker tests. Health minister Karin Smyth emphasized the importance of timely diagnosis for patients to manage symptoms and access support, stating that the government is backing research projects to offer hope for a future where individuals can live longer with more joy.

UKRI is employing a 'fail-fast' approach for this program, requiring projects to demonstrate results and achieve milestones to secure continued funding. This model deviates from traditional grant awarding to ensure rapid delivery of results and to prioritize high-potential projects.

Andy Hill, Health Mission Challenge Director at UKRI, noted that improved diagnostic and prognostic tools can help individuals living with dementia better manage their symptoms, access earlier treatment, and plan for their futures, ultimately improving the quality of life for patients, families, and caregivers.

Hilary Evans-Newton, Chief Executive of Alzheimer's Research UK, highlighted the urgency of shortening the diagnostic pathway, particularly as new medicines are most effective in the early stages of the disease. She stated that backing only effective innovations can expedite their implementation in the NHS.

Dr. Richard Oakley, associate director of research and innovation at Alzheimer's Society, pointed out that one in three individuals with dementia in the UK currently lack a diagnosis, missing out on crucial treatment, support, and research opportunities. He expressed optimism that the Dementia Challenge could significantly shorten the path to diagnosis by rapidly scaling innovative technologies in real-world NHS settings and urged the government to establish a national 18-week target for diagnosis from referral.